OphtiMed Rx

Novel Molecular Treatment for Dry Age-related Macular Degeneration

Health Tech & Life Sciences
Active
Seed Afula, Israel Founded 2021
Last updated 2026-06-18
Total raised
$1.3M
Last: 2021-11
Stage
Seed
Founded
2021
Headcount
4
HQ
Afula, Israel
Sector
Health Tech & Life Sciences

About

OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness. The company’s treatment protects retinal cells from senescence (cellular aging) and can halt the progression of dry AMD.

OphtiMed Rx’s therapy is designed to prevent the loss of vision and independence caused by dry AMD, providing an enormous benefit to patients.

Funding history · 1 round · $1.3M total

2021-11

Q&A

What is OphtiMed Rx's primary focus?
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness.
When was OphtiMed Rx founded?
OphtiMed Rx was founded in November 2021.
What is the total funding raised by OphtiMed Rx to date?
OphtiMed Rx has raised a total of $1,300,000.
Which investor participated in OphtiMed Rx's funding round in November 2021?
G.O Innovation participated in OphtiMed Rx's funding round in November 2021.
What is the current employee count for OphtiMed Rx?
OphtiMed Rx has 1-10 employees.
What is OphtiMed Rx's current product stage?
OphtiMed Rx is currently in the R&D product stage.
Does OphtiMed Rx hold any patents?
Yes, OphtiMed Rx holds 1 patent.
Where is OphtiMed Rx headquartered?
OphtiMed Rx is headquartered in Afula, Israel.

Team · 1

Founder · Co-founder and CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2B

Highlights

1 PatentsVerified

Tags

pharmaceuticalspharma-companiesdrug-discoveryprivate-investorsophthalmologyinvestorseye-diseasesdrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)